Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Trial Profile

A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs Apomorphine (Primary) ; Apomorphine
  • Indications Parkinson's disease
  • Focus Pharmacokinetics; Registrational
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 04 Sep 2018 Planned End Date changed from 29 Aug 2018 to 1 Mar 2019.
    • 04 Sep 2018 Planned primary completion date changed from 29 Aug 2018 to 1 Mar 2019.
    • 07 May 2018 Planned End Date changed from 29 Jun 2018 to 29 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top